Epristeride (SKF-105,657, ONO-9302) is a selective, transition state, non-competitive inhibitor of the type II isoform of the enzyme 5α-reductase, similarly to finasteride and turosteride. It was under development for the treatment of benign prostatic hyperplasia and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline), and reached phase III...